MedTrace Logo

Clinical Use of Stem Cells for the Treatment of Covid-19

NCT04392778 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-05-25

No results posted yet for this study

Summary

This study aims to use the regenerative and repair abilities of stem cells to fight against the harmful effects of the novel coronavirus Covid-19 and therefore develop a treatment strategy. It is known that fatalities from this virus is largely caused by its damage to lungs and other organs. As the disease progresses, these organs fail and lead to mortality. Our hope is that the stem cell transplantation from healthy donors will repair the damage caused by the virus and result in a healthy recovery.

Conditions

  • Covid19
  • Pneumonia
  • Multiple Organ Failure
  • Corona Virus Infection

Interventions

BIOLOGICAL

MSC Treatment

Protocol length: 1 week Doses: 1. Application: 3 million cells/kg IV-------------------------------------------------0 day 2. Application: 3 million cells/kg IV ------------------------------------------------3rd day 3. Application: 3 million cells/kg IV -------------------------------------------------6th day will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

BIOLOGICAL

Saline Control

Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

Sponsors & Collaborators

  • Istinye University

    collaborator OTHER

  • Regenerative Medicine and Stem Cell Production Center Liv MedCell

    collaborator UNKNOWN

  • Liv Hospital (Ulus)

    collaborator UNKNOWN

  • SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi

    lead OTHER

Principal Investigators

  • Gokhan T Adas, Prof.Dr. · SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi

  • Erdal Karaoz, Prof.Dr. · Istinye University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2020-11-01
Completion
2020-11-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04392778 on ClinicalTrials.gov